Parkinson's disease

Baptist Health Foundation Announces Historic $50 Million Gift from Kenneth C. Griffin

Retrieved on: 
Dienstag, März 19, 2024
Citadel, Epilepsy, Baptist Health, Neurology, Baptist Health South Florida, Science, Alzheimer's disease, Incidence, Patient, Research, History, Neuroscience, Parkinson's disease, Baptists, DSM-IV codes, Hospital, Baptist Hospital, Physician, Health, Dementia, Medicine, Pharmaceutical industry

Miami, FL, March 19, 2024 (GLOBE NEWSWIRE) -- Baptist Health Foundation today announced the largest single donation in the nearly 65-year history of Baptist Health South Florida.

Key Points: 
  • Miami, FL, March 19, 2024 (GLOBE NEWSWIRE) -- Baptist Health Foundation today announced the largest single donation in the nearly 65-year history of Baptist Health South Florida.
  • The $50 million gift from Kenneth C. Griffin, founder and CEO of Miami-based hedge fund Citadel and founder of Griffin Catalyst, will advance neurological care in the region.
  • The new Kenneth C. Griffin Center at Miami Neuroscience Institute will also help advance research related to neuroscience and neurodegenerative disorders.
  • “This extraordinary gift is a visionary contribution to the well-being of current and future generations in South Florida and beyond,” said Bo Boulenger, president and CEO of Baptist Health.

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

Retrieved on: 
Montag, März 18, 2024
EEG, U.S. FDA, Schizophrenia, Deficit spending, Data analysis, Memory, Alzheimer's disease, Central nervous system, Part, Delusion, Patient, CNS, ERP, Biomarker, Doctor of Philosophy, Parkinson's disease, Quality of life, Personalized medicine, Life, Trial of the century, Positive, Rett syndrome, Hallucination, PANSS, Therapy, SIGMAR1, DSM-IV codes, FDA, Pharmaceutical industry

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that the first patient in its U.S. FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia has been screened ahead of schedule.

Key Points: 
  • “Initiating our Phase 2 trial of ANAVEX®3-71 in schizophrenia ahead of schedule is a testament to the hard work and dedication of our clinical study team,” stated Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.
  • “Schizophrenia is a challenging disorder that can impair social and occupational functions and overall quality of life for the nearly 24 million people affected worldwide.
  • The placebo-controlled Phase 2, two-part, in-patient trial, ANAVEX®3-71-SZ-001 ( NCT06245213 ), will investigate the effects of ANAVEX®3-71 in patients with schizophrenia.
  • In addition to the electrophysiological biomarkers, Anavex is applying novel neuroinflammatory, metabolomic, and transcriptomic biomarkers at the intersection of schizophrenia pathophysiology and ANAVEX®3-71’s novel, dual mechanism of action.

Rumble Boxing Joins the Fight with The Michael J. Fox Foundation

Retrieved on: 
Mittwoch, April 3, 2024
Philanthropy, Health, Sports, Neurology, Fitness & Nutrition, Boxing, Foundation, PDT, Disease, Partnership, Research, Perspiration, MJFF, Introduction, Fitness, Parkinson's disease, House, Courage, DSM-IV codes, HIIT, Rumble, Multimedia

Rumble Boxing , an Xponential Fitness brand, announced today its continued partnership for the second consecutive year with Team Fox, the grassroots fundraising community of The Michael J.

Key Points: 
  • Rumble Boxing , an Xponential Fitness brand, announced today its continued partnership for the second consecutive year with Team Fox, the grassroots fundraising community of The Michael J.
  • Fox Foundation for Parkinson’s Research (MJFF) to raise funds and garner support for Parkinson’s Awareness Month in April.
  • To amplify the impact, Rumble Boxing is excited to present a multi-city panel tour with Rumble Boxing Co-Founder, Noah Neiman, alongside MJFF community members affected by Parkinson’s.
  • With over 80 studios nationwide, Rumble Boxing pairs boxing, HIIT, metabolic conditioning, and strength training group fitness for a full-body workout for all fitness levels.

Merz Enters Asset Purchase Agreement With a US-Based Biotech Company

Retrieved on: 
Dienstag, April 2, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional Services, Growth, PD, Patient, Merz, Sale, Acquisition, Sclerosis, Parkinson's disease, DSM-IV codes, Therapy, Acorda Therapeutics, Physician, Pharmaceutical industry

Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics.

Key Points: 
  • Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics.
  • Closing of the transaction would significantly contribute to the accelerated growth strategy of Merz Therapeutics.
  • This investment would add significantly to Merz Therapeutics growth strategy and expand our portfolio in the field of movement disorders and neurodegeneration.
  • As a German-based but global company, we are very interested in innovative acquisitions, on a global scale," concludes Jörg Bergler.

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results

Retrieved on: 
Montag, April 1, 2024
Mental Health, Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, PIN, PNH, Patient, Sale, CUD, Graft-versus-host disease, Investment, Clinical trial, Hemolysis, Calcineurin, Emory University, ASH, Risk, L-DOPA, Thumbay Hospital, Behavior informatics, Trial of the century, Myelodysplastic syndrome, Cancer, Safety, Transplant, LID, DRI, BLA, Corporation, Paroxysmal nocturnal hemoglobinuria, Tardive dyskinesia, Parkinson's disease, Publication, DSM-IV codes, Retirement, FDA, PDE7, LDH, Hematology, Mortality, Hematopoietic stem cell transplantation, Bone marrow failure, Abstract, Society, Pharmacology, Pharmaceutical industry

Net loss from continuing operations was $39.3 million for the 2023 fourth quarter compared to $51.7 million for the prior quarter.

Key Points: 
  • Net loss from continuing operations was $39.3 million for the 2023 fourth quarter compared to $51.7 million for the prior quarter.
  • Total operating expenses for the fourth quarter of 2023 were $39.8 million compared to $48.2 million for the third quarter of 2023.
  • Interest expense during the fourth quarter of 2023 was $7.1 million compared to $7.9 million during the prior quarter.
  • During the fourth quarter of 2023, we earned $3.4 million in interest and other income compared to $4.4 million in the third quarter.

PhotoPharmics Launches Largest Phototherapy Trial for Parkinson’s Disease

Retrieved on: 
Dienstag, März 26, 2024
Biotechnology, Neurology, Medical Devices, Health, Clinical Trials, PDQ, Depression, Parkinson's disease, Disease, Sleep, Patient, URMC, Research, Anxiety, University, Telehealth, Hope, Quality of life, Eye, Chet, Light, Clinical trial, Retina, Cognition, MDS, Tremor, Fatigue, FDA, The, Pharmaceutical industry

The "Celeste Light for PD Trial" (found at lightforpd.com) represents a significant stride in Parkinson’s disease (PD) treatment, leveraging innovative Spectramax™ technology through the passive and non-invasive Celeste® phototherapy device.

Key Points: 
  • The "Celeste Light for PD Trial" (found at lightforpd.com) represents a significant stride in Parkinson’s disease (PD) treatment, leveraging innovative Spectramax™ technology through the passive and non-invasive Celeste® phototherapy device.
  • This pivotal trial will assess the efficacy of Celeste®, the company’s FDA Breakthrough phototherapy device to improve non-motor and motor function and quality of life in Parkinson’s disease (PD).
  • This 300-patient phototherapy trial will be the largest trial of its kind.
  • “A pivotal trial for medical devices is similar to a phase 3 trial drug trial,” said Dan Adams, chief science officer.

North America Molecular Diagnostics Market Size, Share & Trends Analysis Report 2024-2030: Growing Prevalence of Target Diseases & Increasing External Funding for R&D Fueling Expansion - ResearchAndMarkets.com

Retrieved on: 
Dienstag, März 26, 2024
Health, Biotechnology, Candidiasis, Diagnosis, PCR, MVP, Conditional sentence, Bacterial vaginosis, Prevalence, Infection, Promega, Country, Thermo Fisher Scientific, SME, Tuberculosis, Application, ISH, RT, HIV, Alzheimer's disease, Incidence, Turner syndrome, Cepheid variable, Research, Trichomoniasis, Real-time, Cancer, Death, Parkinson's disease, CDC, QIAGEN, Therapy, USD, Horvitz–Thompson estimator, Helix, DSM-IV codes, Vaccine

Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.

Key Points: 
  • Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.
  • Molecular diagnostics enable early diagnosis of cancer, genetic disorders, and infectious diseases by using PCR, sequencing, & genetic technologies.
  • In addition, the increasing incidence of diseases, such as influenza A & B, is projected to drive market growth.
  • An increase in external funding to conduct clinical studies in molecular diagnostics is anticipated to fuel the market.

Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease

Retrieved on: 
Dienstag, März 26, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Neurology, Multiple sclerosis, Biomarker, Neuroscience, Parkinson's disease, Biogen, Safety, LUMA, Medtech, Medical imaging

Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson's disease.

Key Points: 
  • Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson's disease.
  • As part of the agreement, Biogen will licence KonectomTM to Indivi, a smartphone-based digital biomarker platform that assesses neurological functions remotely for more precise, frequent measurement of disease evolution.
  • In addition, Biogen and Indivi aim to develop and validate novel digital endpoints in Parkinson’s disease as well as explore additional disease areas for endpoint development leveraging KonectomTM.
  • Indivi uses advanced computational and statistical modelling methods to potentially yield more precise measures of progression of Parkinson’s disease with improved signal-to-noise properties.

Unlearn’s TwinRCT Solution Update Enhances Phase 2 Trial Decision-Making Power

Retrieved on: 
Dienstag, März 19, 2024
Biotechnology, Pharmaceutical, Health, Artificial Intelligence, Data Management, Health Technology, Technology, Clinical Trials, Clutch (eggs), Frontotemporal dementia, Disease, Stroke, Clinical trial, Parkinson's disease, AI, ALS, Medicine, Pharmaceutical industry

Unlearn ®, a company at the forefront of AI in medicine, today announced the newest version of its TwinRCT™ solution, TwinRCT 3.0.

Key Points: 
  • Unlearn ®, a company at the forefront of AI in medicine, today announced the newest version of its TwinRCT™ solution, TwinRCT 3.0.
  • TwinRCTs are randomized clinical trials that use digital twins of trial participants—comprehensive forecasts of individual clinical outcomes—to optimize clinical trials.
  • Unlearn’s updated TwinRCT can now incorporate additional previous clinical trial data to provide an even more robust framework for Phase 2 trial evaluations, which represent a crucial stage in the drug development process.
  • The results of a case study reanalyzing a completed Alzheimer’s Disease study demonstrate that a traditional trial would require 23% more trial participants to achieve the same power as Unlearn’s updated TwinRCT.

Cognito Therapeutics Announces Spectris™ OVERTURE OLE Study Data Supports Potential Disease Modification and Early Treatment in Alzheimer’s Disease

Retrieved on: 
Montag, März 11, 2024
Software, Research, Hardware, Pharmaceutical, Data Management, Technology, Medical Devices, Clinical Trials, Science, Neurology, Biotechnology, Health, Other Science, Cognito, Conference, MRI, HOPE, Parkinson's disease, Disease, Patient, Amyloid-related imaging abnormalities, OLE, ARIA, Clinical trial, Therapy, Safety, WBV, Pharmaceutical industry

The results support for Spectris’™ potential as a disease modifying therapy that, if approved, could also be used as an early intervention for the treatment of Alzheimer’s Disease (AD).

Key Points: 
  • The results support for Spectris’™ potential as a disease modifying therapy that, if approved, could also be used as an early intervention for the treatment of Alzheimer’s Disease (AD).
  • These results provide support for the potential safety of prolonged treatment and highlight the potential for Spectris as a potential disease modifying therapy to preserve both brain structure and function in patients with AD,” said Brent Vaughan, CEO of Cognito Therapeutics.
  • 83% of the OVERTURE study patients (44/53) entered a separate 12-month open label extension (OLE) study, which allowed for further evaluation of Spectris’ potential as a disease modifying therapy.
  • “These results are consistent with accepted criteria for disease modification and support potential for use as early treatment of AD.